EXPLORE THE SCIENCE
TL;DR: A 2026 Phase 2 trial in The British Journal of Psychiatry found that 10 mg emestedastat did not improve attention and working memory after six weeks in adults with major depressive disorder and objectively measured cognitive impairment. A nominal depres…
Read article
TL;DR: A 2026 randomized trial in Journal of Medical Internet Research tested the web-based Health Check-Up for Expectant Moms program in 176 pregnant women at risk for substance use or sexually transmitted infection risk, but reductions in alcohol, cannabis,…
Read article
TL;DR: A 2026 randomized trial in BMC Anesthesiology found that adding an esketamine-adjuvanted stellate ganglion block to intraoperative esketamine plus dexmedetomidine reduced early postoperative sleep disturbance after gynecological laparoscopic surgery. Ke…
Read article
TL;DR: A 2026 qualitative study in the Journal of Substance Use and Addiction Treatment found that syringe service programs helped people receive buprenorphine quickly, but participants said precipitated withdrawal and limited at-home initiation guidance made…
Read article
TL;DR: A 2026 pilot study in The British Journal of Psychiatry tested psilocybin-assisted therapy in 21 adult females with anorexia nervosa and found lower Eating Disorder Examination (EDE) symptom scores through 6 months, with large individual variation and n…
Read article
TL;DR: A 2026 retrospective chart review in Acta Psychiatrica Scandinavica found that a psychiatrist-led metabolic clinic helped 132 of 378 patients with severe mental illness lose at least 5% of baseline body weight over 12 months. Key Findings Clinic outcome…
Read article
TL;DR: A 2026 preprint on medRxiv found that adding 24 IU intranasal oxytocin before 4 mindfulness-based group therapy sessions was linked to larger clinician-rated negative-symptom improvements in a small schizophrenia spectrum disorder pilot trial. Key Findi…
Read article
TL;DR: A 2026 review in Brain Medicine found mixed randomized-trial evidence for creatine monohydrate as an add-on depression treatment: 2 of 5 trials showed symptom benefits, while 3 did not find a clear advantage. Key Findings Five randomized trials were rev…
Read article
TL;DR: A 2026 study in Signal Transduction and Targeted Therapy engineered a modified inhibitory DREADD receptor called GRANPA so the over-the-counter antihistamine diphenhydramine could switch off targeted brain circuits and reduce seizure activity in mouse m…
Read article
TL;DR: A 2026 narrative review in Clinical Drug Investigation argued that desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI), may be a first-line major depressive disorder option for selected patients, especially when fatigue, cognitive compla…
Read article